Search Result

Results for "

Chemotaxis Inhibitors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (2) Antibiotic (1) Autophagy (2) c-Kit (1) Cathepsin (1) CCR (14) Chemerin Receptor (1) Complement System (2) CXCR (2) Cytochrome P450 (1) Drug Metabolite (1) ERK (2) Filovirus (1) Formyl Peptide Receptor (FPR) (1) GPR84 (1) Histamine Receptor (9) HuR (1) Isotope-Labeled Compounds (2) Leukotriene Receptor (2) NF-κB (1) p38 MAPK (1) Parasite (1) Phosphatase (2) Phospholipase (2) Proteasome (1) Protein Arginine Deiminase (1) Reactive Oxygen Species (1) RET (1) SARS-CoV (2) Src (2) VEGFR (1)
By Research Areas:	Cancer (9) Cardiovascular Disease (1) Endocrinology (7) Infection (2) Inflammation/Immunology (30) Neurological Disease (3)

By Targets:

Akt (2)

Antibiotic (1)

Autophagy (2)

c-Kit (1)

Cathepsin (1)

CCR (14)

Chemerin Receptor (1)

Complement System (2)

CXCR (2)

Cytochrome P450 (1)

Drug Metabolite (1)

ERK (2)

Filovirus (1)

Formyl Peptide Receptor (FPR) (1)

GPR84 (1)

Histamine Receptor (9)

HuR (1)

Isotope-Labeled Compounds (2)

Leukotriene Receptor (2)

NF-κB (1)

p38 MAPK (1)

Parasite (1)

Phosphatase (2)

Phospholipase (2)

Proteasome (1)

Protein Arginine Deiminase (1)

Reactive Oxygen Species (1)

RET (1)

SARS-CoV (2)

Src (2)

VEGFR (1)

By Research Areas:

Cancer (9)

Cardiovascular Disease (1)

Endocrinology (7)

Infection (2)

Inflammation/Immunology (30)

Neurological Disease (3)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P3982

CKLF1-C19	CCR	Inflammation/Immunology
CKLF1-C19 is the C-terminal peptide of human chemokine-like factor 1 (CKLF1). CKLF1-C19 interacts with CCR4, and inhibits chemotaxis induced by both CKLF1 and CCL17. CKLF1-C19 can suppress allergic lung inflammation via inhibiting chemotaxis mediated by CCR3 and CCR4 .

HY-124416

ML604086	CCR	Inflammation/Immunology Endocrinology
ML604086 is a selective CCR8 inhibitor, inhibiting CCL1 binding to CCR8 on circulating T-cells. ML604086 inhibits CCL1 mediated chemotaxis and increases in intracellular Ca ²⁺ concentrations .

HY-103360B

trans-J-113863	CCR	Inflammation/Immunology
trans-J-113863 is a potent chemokine CCR1 and CCR3 receptor antagonist, and inhibits MIP-1α-induced chemotaxis in CCR1 transfectants and eotaxin-induced chemotaxis in CCR3 transfectants with IC₅₀ of 9.57 and 93.8 nM,respectively .

HY-125567

Antileukinate	CXCR	Inflammation/Immunology
Antileukinate, a hexapeptide, is a potent inhibitor of CXC-chemokine receptor (CXCR). Antileukinate inhibits neutrophil chemotaxis and activation. Antileukinate can be used for the research of acute inflammation and injury .

HY-155300

BLT2 antagonist-1	Leukotriene Receptor	Inflammation/Immunology
BLT2 antagonist-1 (compound 15b) is a selective BLT2 antagonist that inhibits the chemotaxis of CHO-BLT2 cells with an IC₅₀ of 224 nM. BLT2 antagonist-1 does not inhibits the chemotaxis of CHO-BLT1 cells. BLT2 antagonist-1 also inhibits the binding of LTB4 and BLT2 with a K_i value of 132 nM. BLT2 antagonist-1 can be used for the research of the inflammatory airway diseases such as asthma and chronic obstructive pulmonary disease .

HY-122219

R243	CCR	Inflammation/Immunology
R243 is a potent and selective CCR8 antagonist. R243 inhibits CCL₁/CCR8 interaction and inhibits CCR8 signaling and chemotaxis. R243 has antinociceptive and anti-inflammatory effects .

HY-109011

Rosiptor 3 Publications Verification AQX-1125	Phosphatase	Cancer
Rosiptor (AQX-1125) is a selective and orally active phosphatase SHIP1 activator with anti-inflammatory effects. Rosiptor (AQX-1125) inhibits Akt phosphorylation, inflammatory mediator production and leukocyte chemotaxis in vitro .

HY-109011A

Rosiptor acetate AQX-1125 acetate	Phosphatase	Cancer
Rosiptor (AQX-1125) acetate is a selective and orally active phosphatase SHIP1 activator with anti-inflammatory effects. Rosiptor acetate (AQX-1125) inhibits Akt phosphorylation, inflammatory mediator production and leukocyte chemotaxis in vitro .

HY-126536

ChemR23-IN-1	Chemerin Receptor	Inflammation/Immunology
ChemR23-IN-1 (compound 2) is a ChemR23 inhibitor with IC₅₀s of 38 nM and 100 nM for human and mouse ChemR23, respectively. ChemR23-IN-1 inhibits chemotaxis of CAL-1 triggered by Chemerin in vitro .

HY-153450

JBI-589	Protein Arginine Deiminase	Cancer
JBI-589 is a non-covalent PAD4 isoform-selective inhibitor. JBI-589 reduces CXCR2 expression and blocks neutrophil chemotaxis. JBI-589 reduces primary tumor and metastases, and enhances the anti-tumor effect of checkpoint inhibitors .

HY-123763

MLN3126	CCR	Inflammation/Immunology
MLN3126 is an orally active and potent CCR9 antagonist. MLN3126 inhibits CCL25-induced calcium mobilization and chemotaxis of mouse primary thymocytes, wiht an IC₅₀ value of 6.3 nM for calcium influx .

HY-17042

Cetirizine 2 Publications Verification	Histamine Receptor	Inflammation/Immunology Endocrinology
Cetirizine, a second-generation antihistamine and the carboxylated metabolite of hydroxyzine, is a specific, orally active and long-acting histamine H1-receptor antagonist. Cetirizine marks antiallergic properties and inhibits eosinophil chemotaxis during the allergic response .

HY-17042A

Cetirizine dihydrochloride 2 Publications Verification P071	Histamine Receptor	Inflammation/Immunology Endocrinology
Cetirizine dihydrochloride, a second-generation antihistamine and the carboxylated metabolite of hydroxyzine, is a specific, orally active and long-acting histamine H1-receptor antagonist. Cetirizine dihydrochloride marks antiallergic properties and inhibits eosinophil chemotaxis during the allergic response .

HY-108323

CCR2 antagonist 4 3 Publications Verification Teijin compound 1	CCR	Inflammation/Immunology
CCR2 antagonist 4 (Teijin compound 1) is a potent and specific CCR2 antagonist, with IC₅₀s of 180 nM for CCR2b. CCR2 antagonist 4 potently inhibits MCP-1-induced chemotaxis with an IC₅₀ of 24 nM .

HY-103362

CCR2 antagonist 4 hydrochloride 3 Publications Verification Teijin compound 1 hydrochloride	CCR	Inflammation/Immunology
CCR2 antagonist 4 hydrochloride (Teijin compound 1 hydrochloride) is a potent and specific CCR2 antagonist, with IC₅₀s of 180 nM for CCR2b. CCR2 antagonist 4 hydrochloride potently inhibits MCP-1-induced chemotaxis with an IC₅₀ of 24 nM .

HY-100660A

Cetirizine Impurity B dihydrochloride	Drug Metabolite	Others
Cetirizine Impurity B dihydrochloride is an impurity of Cetirizine dihydrochloride. Cetirizine, a second-generation antihistamine, is a specific, orally active and long-acting histamine H1-receptor antagonist. Cetirizine marks antiallergic properties and inhibits eosinophil chemotaxis during the allergic response .

HY-100661

Cetirizine Impurity D	Histamine Receptor	Inflammation/Immunology Endocrinology
Cetirizine Impurity D is an impurity of Cetirizine. Cetirizine, a second-generation antihistamine, is a specific, orally active and long-acting histamine H1-receptor antagonist. Cetirizine marks antiallergic properties and inhibits eosinophil chemotaxis during the allergic response .

HY-15724

Vercirnon 1 Publications Verification GSK-1605786; CCX282-B; Traficet-EN	CCR	Inflammation/Immunology Endocrinology
Vercirnon (GSK1605786A) is an orally bioavailable, selective, and potent antagonist of CCR9. Vercirnon inhibits CCR9-mediated Ca ²⁺ mobilization and chemotaxis on Molt-4 cells with IC₅₀ values of 5.4 and 3.4 nM, respectively. Vercirnon is selective for CCR9 over CCR1-12 and CX3CR1-7 (IC₅₀s>10 µM for all). Vercirnon is an equipotent inhibitor of CCL25-directed chemotaxis of both splice forms of CCR9 (CCR9A and CCR9B) with IC₅₀ values of 2.8 and 2.6 nM, respectively .

HY-15724A

Vercirnon sodium 1 Publications Verification GSK-1605786 sodium; CCX282-B sodium; Traficet-EN sodium	CCR	Inflammation/Immunology Endocrinology
Vercirnon (GSK1605786A) sodium is an orally bioavailable, selective, and potent antagonist of CCR9. Vercirnon sodium inhibits CCR9-mediated Ca ²⁺ mobilization and chemotaxis on Molt-4 cells with IC₅₀ values of 5.4 and 3.4 nM, respectively. Vercirnon sodium is selective for CCR9 over CCR1-12 and CX3CR1-7 (IC₅₀s>10 µM for all). Vercirnon sodium is an equipotent inhibitor of CCL25-directed chemotaxis of both splice forms of CCR9 (CCR9A and CCR9B) with IC₅₀ values of 2.8 and 2.6 nM, respectively .

HY-148853

SRI-42127	HuR	Others
SRI-42127 is a HuR translocation inhibitor. HuR is an RNA regulator that binds to AREs, and HuR translocations promote the production of inflammatory cytokines in glial cells. However, SRI-42127 can destroy mRNA stability and inhibit gene promoter activation. SRI-42127 also inhibits microglial cell activation and attenuates recruitment/chemotaxis of neutrophils and monocytes .

HY-17042AS

Cetirizine-d4 dihydrochloride	Isotope-Labeled Compounds Histamine Receptor	Inflammation/Immunology
Cetirizine-d₄ (dihydrochloride) is a deuterium labeled Cetirizine. Cetirizine, a second-generation antihistamine and the carboxylated metabolite of hydroxyzine, is a specific, orally active and long-acting histamine H1-receptor antagonist. Cetirizine marks antiallergic properties and inhibits eosinophil chemotaxis during the allergic response[1][2][3].

HY-17042AS1

Cetirizine-d8 dihydrochloride	Isotope-Labeled Compounds Histamine Receptor	Inflammation/Immunology
Cetirizine-d₈ (dihydrochloride) is a deuterium labeled Cetirizine. Cetirizine, a second-generation antihistamine and the carboxylated metabolite of hydroxyzine, is a specific, orally active and long-acting histamine H1-receptor antagonist. Cetirizine marks antiallergic properties and inhibits eosinophil chemotaxis during the allergic response[1][2][3].

HY-17042S

Cetirizine-d4	Histamine Receptor	Inflammation/Immunology
Cetirizine-d₄ is a deuterium labeled Cetirizine. Cetirizine, a second-generation antihistamine and the carboxylated metabolite of hydroxyzine, is a specific, orally active and long-acting histamine H1-receptor antagonist. Cetirizine marks antiallergic properties and inhibits eosinophil chemotaxis during the allergic response[1][2][3].

HY-17042S1

Cetirizine-d8	Histamine Receptor	Inflammation/Immunology
Cetirizine-d₈ is a deuterium labeled Cetirizine. Cetirizine, a second-generation antihistamine and the carboxylated metabolite of hydroxyzine, is a specific, orally active and long-acting histamine H1-receptor antagonist. Cetirizine marks antiallergic properties and inhibits eosinophil chemotaxis during the allergic response[1][2][3].

HY-116171

(Rac)-Calpain Inhibitor XII	Proteasome	Cardiovascular Disease Neurological Disease
(Rac)-Calpain Inhibitor XII is a reversible and selective inhibitor of calpain I (μ-calpain, K_i=19 nM). (Rac)-Calpain Inhibitor XII has lower affinities for calpain II (m-calpain, K_i=120 nM) and cathepsin B (K_i=750 nM). (Rac)-Calpain Inhibitor XII has the potential for studying the role of calpains in diverse processes, including neutrophil chemotaxis, neuronal signaling, and cardiac response to injury .

HY-N0634

Cimifugin 1 Publications Verification Cimitin	NF-κB	Inflammation/Immunology
Cimifugin (Cimitin) is a bioactive component of Cimicifuga racemosa, a Chinese herb. Cimifugin suppresses allergic inflammation by reducing epithelial derived initiative key factors via regulating tight junctions . Cimifugin reduces the migration and chemotaxis of RAW264.7 cells and inhibits the release of inflammatory factors and activation of MAPKs and NF-κB signaling pathways induced by LPS .

HY-12807

FIPI 4 Publications Verification 5-Fluoro-2-indolyl deschlorohalopemide	Phospholipase Autophagy	Inflammation/Immunology Cancer
FIPI (5-Fluoro-2-indolyl des-chlorohalopemide), a derivative of Halopemide (HY-119093), is a phospholipase D (PLD) inhibitor with IC₅₀s of approximately 25 nM and 20 nM for PLD1 and PLD2, respectively. FIPI inhibits PLD regulation of F-actin cytoskeleton reorganization, cell spreading, and chemotaxis. FIPI has the potential for autoimmunity and cancer metastasis research .

HY-P99520

Vilobelimab CaCP-29, IFX-1	Complement System SARS-CoV	Infection Inflammation/Immunology
Vilobelimab (CaCP-29, IFX-1) is a monoclonal anti-C5a antibody to the allergen C5a, a pro-inflammatory complement division product that plays a central role in mediating organ dysfunction. Vilobelimab acts as a C5a inhibitor, inhibiting neutrophil activation, chemotaxis, and reducing inflammatory signalling, and may be used in studies related to sepsis, COVID-19, etc .

HY-12807A

FIPI hydrochloride 5-Fluoro-2-indolyl deschlorohalopemide hydrochloride	Phospholipase Autophagy	Inflammation/Immunology Cancer
FIPI (5-Fluoro-2-indolyl des-chlorohalopemide) hydrochloride, a derivative of Halopemide (HY-119093), is a phospholipase D (PLD) inhibitor with IC₅₀s of approximately 25 nM and 20 nM for PLD1 and PLD2, respectively. FIPI hydrochloride inhibits PLD regulation of F-actin cytoskeleton reorganization, cell spreading, and chemotaxis. FIPI hydrochloride has the potential for autoimmunity and cancer metastasis research .

HY-13499

JNJ-41443532 CCR2 antagonist 5	CCR	Inflammation/Immunology
JNJ-41443532 (CCR2 antagonist 5) is a selective, orally active hCCR2 inhibitor with good binding affinity (IC₅₀=37 nM) and potent functional antagonism (chemotaxis IC₅₀=30 nM). JNJ-41443532 displays a K_i of 9.6 µM for mCCR2 binding. JNJ-41443532 can be used in the research of inflammatory disease .

HY-145697

GPR84 antagonist 2	GPR84	Inflammation/Immunology
GPR84 antagonist 2 (compound 33) is a potent, selective, and orally active GPR84 antagonist (IC₅₀=8.95 nM). GPR84 antagonist 2 shows improved potency in the calcium mobilization assay and the ability to inhibit the chemotaxis of neutrophils and macrophages upon GPR84 activation. GPR84 antagonist 2 has the potential for the research of ulcerative colitis .

HY-B0174A

Olsalazine	Leukotriene Receptor Antibiotic	Inflammation/Immunology
Olsalazine is a potent inhibitor of macrophages chemotaxis to LTB4 with an IC₅₀ value of 0.39 mM, also reduces the synthesis of 5-hydroxyeicosatetraenoic acid (5-HETE), 11-HETE, 12-HETE, and 15-HETE in polymorphonuclear leukocyte (PMNL) and mononuclear cells (MNL). Olsalazine can be used for researching ulcerative colitis. Anti-inflammatory activity .

HY-123532

JNJ10191584 VUF6002	Histamine Receptor	Neurological Disease
JNJ10191584 (VUF6002) is an orally active and selective histamine H₄ receptor antagonist with a K_i value of 26 nM. JNJ10191584 shows 540-fold selectivity to H₄ receptor over H₃ receptor with a K_i value of 14.1 μM. JNJ10191584 inhibits chemotaxis of eosinophils and mast cells with IC₅₀ values of 530 nM and 138 nM, respectively .

HY-103364A

C-021 dihydrochloride 1 Publications Verification	CCR	Inflammation/Immunology
C-021 dihydrochloride is a potent CC chemokine receptor-4 (CCR4) antagonist. C-021 dihydrochloride potently inhibits functional chemotaxis in human and mouse with IC₅₀s of 140 nM and 39 nM, respectively. C-021 dihydrochloride effectively prevents human CCL22-derived [ ³⁵S]GTPγS from binding to the receptor with an IC₅₀ of 18 nM .

HY-125836

CCR4 antagonist 2	CCR	Endocrinology Cancer
CCR4 antagonist 2 (Compound 31) is a novel potent, orally bioavailable small molecule antagonists of CC chemokine receptor 4 (CCR4) that inhibits T_reg trafficking into the Tumor Microenvironment without suppressing the number of Treg in healthy tissues. CCR4 antagonist 2 (Compound 31) exhibits IC₅₀ values of Ca ²⁺flux and (chemotaxis) CTX are 40 nM and 70 nM, respectively .

HY-103364

C-021 1 Publications Verification	CCR	Inflammation/Immunology
C-021 is a potent CC chemokine receptor-4 (CCR4) antagonist. C-021 potently inhibits functional chemotaxis in human and mouse with IC₅₀s of 140 nM and 39 nM, respectively. C-021 effectively prevents human CCL22-derived [ ³⁵S]GTPγS from binding to the receptor with an IC₅₀ of 18 nM .

HY-107558

JNJ10191584 maleate VUF6002 maleate	Histamine Receptor	Neurological Disease
JNJ10191584 (VUF6002) maleate (compound 40) is an orally active and selective histamine H₄ receptor antagonist with a K_i value of 26 nM. JNJ10191584 maleate shows 540-fold selectivity to H₄ receptor over the H₃ receptor with a K_i value of 14.1 μM. JNJ10191584 maleate inhibits chemotaxis of eosinophils and mast cells with IC₅₀ values of 530 nM and 138 nM, respectively .

HY-16992A

W-54011 4 Publications Verification	Complement System Reactive Oxygen Species	Inflammation/Immunology
W-54011 is a potent and orally active non-peptide C5a receptor antagonist. W-54011 inhibits the binding of ¹²⁵I-labeled C5a to human neutrophils with a K_i value of 2.2 nM. W-54011 also inhibits C5a-induced intracellular Ca ²⁺ mobilization, chemotaxis, and generation of ROS in human neutrophils with IC₅₀s of 3.1 nM, 2.7 nM, and 1.6 nM, respectively .

HY-146372

CXCR4 antagonist 5	CXCR	Cancer
CXCR4 antagonist 5 (compound 23) is a highly potent CXCR4 antagonist with an IC₅₀ value of 8.8 nM. CXCR4 antagonist 5 can inhibit CXCL12-induced cytosolic calcium increase (IC₅₀ = 0.02 nM) and inhibits CXCR4/CXLC12-mediated chemotaxis. CXCR4 antagonist 5 has good physicochemical properties and in vitro safety profiles, inhibiting CYP isozymes and hERG marginally or moderately .

HY-119293

K777 1 Publications Verification	Cathepsin CCR Cytochrome P450 Parasite SARS-CoV Filovirus	Infection Cancer
K777 is a potent, orally active and irreversible cysteine protease inhibitor. K777 is also a potent CYP3A4 inhibitor with an IC₅₀ of 60 nM and a selective CCR4 antagonist featuring the potent chemotaxis inhibition. K777 irreversibly inhibits Cruzain, the major cysteine protease of Trypansoma cruzi, and cathepsins B and L. K777 is a broad-spectrum antiviral by targeting cathepsin-mediated cell entry. K777 inhibits SARS-CoV and EBOV pseudovirus entry with IC₅₀ values of 0.68 nM and 0.87 nM, respectively .

HY-101283

HCH6-1 3 Publications Verification
HCH6-1 is a potent and competitive dipeptide antagonist of Formyl peptide receptor 1 (FPR1). HCH6-1 inhibits chemotaxis, superoxide anion generation, and elastase release in human neutrophils specifically activated by fMLF (an FPR1 agonist). HCH6-1 has protective effects against acute lung injury (ALI) in vivo and can be used for the research of FPR1-involved inflammatory lung diseases .

HY-W744699

Larixol (+)-Larixol	Src ERK Akt	Inflammation/Immunology
Larixol is an fMLP inhibitor and also inhibits Src kinase, ERK1/2, p38 and AKT phosphorylation signals in immune regulation. Larixol can interfere with the interaction between the βγ subunit of the fMLP receptor Gi protein and its downstream molecules, thereby inhibiting fMLP-induced respiratory burst. Larixol inhibits fMLP (0.1 μM)-induced superoxide anion production (IC₅₀: 1.98 μM), cathepsin G release (IC₅₀: 2.76 μM), and chemotaxis. Larixol improves neutrophil hyperactivation and reduces inflammation or tissue damage. A series of Larixol derivatives were found to have inhibitory effects on FSGS-related TRPC6 functional mutants .

HY-W745090

Isomaltulose monohydrate	Formyl Peptide Receptor (FPR) Src ERK Akt p38 MAPK	Others
Isomaltulose monohydrate is a fMLP inhibitor and also inhibits Src kinase, ERK1/2, p38 and AKT phosphorylation signals in immune regulation. Isomaltulose monohydrate can interfere with the interaction between the βγ subunit of the fMLP receptor Gi protein and its downstream molecules, thereby inhibiting fMLP-induced respiratory burst. Isomaltulose monohydrate inhibits fMLP (0.1 μM)-induced superoxide anion production (IC₅₀: 1.98 μM) , cathepsin G release (IC< sub>50: 2.76 μM) and chemotaxis. Isomaltulose monohydrate can improve excessive activation of neutrophils and reduce inflammation or tissue damage. A series of derivatives of Isomaltulose monohydrate are found to have inhibitory effects on FSGS-related TRPC6 functional mutants .

HY-116116

Tafetinib SIM010603	c-Kit RET VEGFR	Cancer
Tafetinib (SIM010603) is an oral multi-targets receptor tyrosine kinases inhibitor. Tafetinib inhibitsstem cell factor receptor (Kit),vascular endothelial growth factor receptor-2 (VEGFR-2),platelet-derived growth factor receptor-β (PDGFR-β),glial cell line-derived neurotrophic factor receptor (Rearranged during Transfection; RET), andFms-like tyrosine kinase-3 (FLT3)withIC₅₀values between 5.0 and 68.1 nmol/l. Tafetinib inhibits the phosphorylation ofPDGFR-βandVEGFR-2. Tafetinib inhibits endothelial cell proliferation, endothelial cells chemotaxis, and corneal angiogenesis .

Isomaltulose monohydrate	Biochemical Assay Reagents
Isomaltulose monohydrate is a fMLP inhibitor and also inhibits Src kinase, ERK1/2, p38 and AKT phosphorylation signals in immune regulation. Isomaltulose monohydrate can interfere with the interaction between the βγ subunit of the fMLP receptor Gi protein and its downstream molecules, thereby inhibiting fMLP-induced respiratory burst. Isomaltulose monohydrate inhibits fMLP (0.1 μM)-induced superoxide anion production (IC₅₀: 1.98 μM) , cathepsin G release (IC< sub>50: 2.76 μM) and chemotaxis. Isomaltulose monohydrate can improve excessive activation of neutrophils and reduce inflammation or tissue damage. A series of derivatives of Isomaltulose monohydrate are found to have inhibitory effects on FSGS-related TRPC6 functional mutants .

Cat. No.	Product Name	Category	Target	Chemical Structure